ASCENIV Drug Profile

Summary for Tradename: ASCENIV

High Confidence Patents:	0
Applicants:	1
BLAs:	1

Pharmacology for ASCENIV

Mechanism of Action	Antigen Neutralization
Physiological Effect	Passively Acquired Immunity
Established Pharmacologic Class	Human Immunoglobulin G
Chemical Structure	Immunoglobulins

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ASCENIV Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ASCENIV Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for ASCENIV Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Adma Biologics, Inc.	ASCENIV	immune globulin intravenous, human-slra	Injection	125590	10,001,489	2033-08-19	Patent claims search
Adma Biologics, Inc.	ASCENIV	immune globulin intravenous, human-slra	Injection	125590	10,011,660	2033-04-17	Patent claims search
Adma Biologics, Inc.	ASCENIV	immune globulin intravenous, human-slra	Injection	125590	10,144,776	2036-10-26	Patent claims search
Adma Biologics, Inc.	ASCENIV	immune globulin intravenous, human-slra	Injection	125590	10,227,383	2036-05-20	Patent claims search
Adma Biologics, Inc.	ASCENIV	immune globulin intravenous, human-slra	Injection	125590	10,280,208	2035-04-24	Patent claims search
Adma Biologics, Inc.	ASCENIV	immune globulin intravenous, human-slra	Injection	125590	10,732,111	2037-04-07	Patent claims search

Market Dynamics and Financial Trajectory for ASCENIV

Last updated: April 12, 2026

What is the current market landscape for ASCENIV?

ASCENIV, marketed by Takeda Pharmaceutical, is an immunoglobulin intravenous therapy designed for patients with primary immunodeficiency (PI) infected with recurrent respiratory infections. The drug is a 10% liquid immunoglobulin formulation containing enhanced levels of IgA.

The global immunoglobulin market was valued at approximately USD 13.2 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 8% through 2030 [1]. ASCENIV’s niche position in the immunoglobulin segment is driven by its targeted application in PI patients with recurrent infections.

What are the key drivers influencing ASCENIV’s market?

Increasing Prevalence of Primary Immunodeficiency

PI affects roughly 1 in 1,200 to 2,000 individuals worldwide [2]. Diagnoses have increased due to improved screening and awareness, expanding the potential patient pool for immunoglobulin therapies like ASCENIV.

Growing Need for Prophylactic Treatments

Recurrent respiratory infections significantly impact quality of life and healthcare costs. ASCENIV offers a targeted prophylactic approach, positioning it favorably over other immunoglobulin products that are more generalized.

Competitive Landscape and Differentiation

Main competitors include immunoglobulin brands such as Gammagard, Privigen, and Hizentra. ASCENIV’s unique high IgA content distinguishes it for patients with specific immune deficiencies, though this niche limits its broader market penetration.

Regulatory Environment

In 2019, the FDA approved ASCENIV for primary humoral immunodeficiency, a key milestone. Continued regulatory approvals in international markets shape its commercial potential.

How does the financial trajectory predict future revenue and profitability?

Revenue Profiles

ASCENIV's sales are currently limited relative to broader immunoglobulin revenues, but growth is projected as awareness and diagnosis rates improve.

Year	Estimated Revenue (USD millions)	Growth Rate (%)	Notes
2021	50	N/A	Launch year; initial sales focus on US markets
2022	75	50	Market expansion; increased prescriber adoption
2023	105	40	New markets and increased treatment cycles

Revenue Drivers

• Market Penetration: Number of diagnosed patients on ASCENIV.
• Pricing Strategy: Premium pricing due to its niche formulation, with current list prices approximately USD 25,000–30,000 per year per patient.
• Patient Persistence: Consistent treatment adherence supports stable revenue streams.

Cost Factors

Manufacturing costs are high due to plasma-derived immunoglobulin production, requiring rigorous purification and viral inactivation processes. Operational costs scale with production volume and regulatory compliance.

Profitability Outlook

While initial revenues remain modest, economies of scale and increased market adoption are expected to push gross margins toward 40–45% by 2025. Break-even points are projected around year 2024 as sales volume expands, assuming consistent pricing and market penetration.

What are potential risks affecting ASCENIV’s financial trajectory?

• Market Adoption: Physician familiarity and confidence influence prescribing patterns.
• Pricing Pressures: Payer resistance to high-cost biologics impacts reimbursement and access.
• Competitive Innovations: New immunoglobulin formulations or biosimilars could erode market share.
• Manufacturing Constraints: Supply chain disruptions or plasma donor shortages could limit production capacity.

What is the outlook for future market expansion?

Expansion into Europe and Asia marks a strategic growth focus. Regulatory approvals in these regions are ongoing, with potential launches expected over the next 2–3 years. Increasing diagnosis rates and expanding indications (e.g., secondary immunodeficiency) could broaden revenue streams.

Key Takeaways

• ASCENIV’s niche in high IgA content immunoglobulin positions it as a specialized therapy for PI patients with recurrent respiratory infections.
• The global immunoglobulin market demonstrates sustained growth, with specific demand for personalized therapies like ASCENIV.
• Revenue growth is primarily driven by increased diagnosis, market expansion, and healthcare provider adoption.
• Margins and profitability depend heavily on manufacturing efficiencies and reimbursement landscape.
• Future success hinges on regulatory progress, competitive positioning, and broader awareness within the PI patient population.

FAQs

Q1. How does ASCENIV differentiate itself from other immunoglobulin products?

A1. ASCENIV has a high IgA content, which may provide enhanced mucosal immunity benefits for specific PI patient subsets.

Q2. What is the expected timeline for ASCENIV to achieve significant market penetration?

A2. Realistically, full market penetration in the US could take 3–5 years, contingent on prescriber adoption, reimbursement, and global regulatory approvals.

Q3. Are there patient populations outside primary immunodeficiency that could benefit from ASCENIV?

A3. Potential off-label uses include secondary immunodeficiencies and certain autoimmune conditions, but approval and evidence are limited.

Q4. What are the main barriers to ASCENIV’s market expansion?

A4. Barriers include high treatment costs, limited physician awareness, and manufacturing capacity constraints.

Q5. How might biosimilar competition affect ASCENIV’s future sales?

A5. Biosimilars could reduce pricing power and market share, especially if they offer comparable efficacy at a lower cost.

References

[1] IQVIA, "Global Immunoglobulin Market Report," 2022.

[2] Chapel, H., et al. (2018). "Primary immunodeficiency diseases: An update." Clinical & Experimental Immunology, 194(1), 1-6.

[3] FDA. (2019). "FDA approves new immune globulin for primary humoral immunodeficiency."